Switzerland· 66696002

Cerdelga

A eliglustat product containing eliglustatum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC A16AX10

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedCerdelgaATCA16AX10REGISTER NO.66696002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Eliglustat is registered in 17 of 19 countries.

Countries holding a registration under ATC A16AX10 (eliglustat), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 11 of them publish a price we can compare per daily dose

Eliglustat · ATC A16AX10

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of eliglustat costs, country by country.

Normalised to the WHO defined daily dose (0.168 g), so markets compare like for like.

  • Switzerland: $1116.28 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Eliglustat · price per daily dose (0.168 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1116.28
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
eliglustatum
Manufacturer
—
Country
Switzerland (CH)
ATC code
A16AX10
ATC class
Eliglustat
Defined daily dose
0.168 g, O
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680666960028
    Blist 56 Stk
    CHF 26044.7

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

336 interactions on record for eliglustat.

Graded by severity as the source publishes them — 119 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Eliglustat · interactions on record

336 records

  • 119 severe
  • 210 moderate
  • 7 minor

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • CimetidineA02BA01severe
  • DiphenhydraminA04AB05severe
  • AprepitantA04AD12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eliglustat in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eliglustat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Cerdelga
  • Liechtenstein · Cerdelga
  • Norway · Cerdelga

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5fac6ca7-f201-4897-a314-9aa5ab0bceb5
GET /v1/drugs/5fac6ca7-f201-4897-a314-9aa5ab0bceb5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "eliglustatum 84.4 mg",
  "valid_from": "2022-06-01",
  "limitations": "[{\"description\":\"Zur Monotherapie bei erwachsenen Patienten ab 18 Jahren mit gesicherter Diagnose eines Morbus Gaucher Typ I, die in Bezug auf Cytochrom-P450 Typ2D6 (CYP2D6) langsame Metabolisierer (poor metabolizers, PMs), intermediäre Metabolisierer (intermediate metabolizers, lMs) oder schnelle Metabolisierer (extensive metabolizers, EMs) sind. Kein Einsatz bei ultraschnellen Metabolisierern oder unklarem Metabolisierungsstatus in Bezug auf Cytochrom-P450 Typ 2D6 (CYP2D6).<br> \\nDie Bestimmung des CYP2D6-Metabolisierungsstatus muss vor der Therapie mit einer validierten Testmethode erfolgen. Die Kosten für den Test werden von sanofi-aventis (suisse) sa übernommen.<br> \\nDie Erstverordnung darf nur durch ein auf hereditäre Stoffwechselerkrankungen spezialisiertes Zentrum oder einen Facharzt/eine Fachärztin mit Erfahrung auf dem Gebiet von hereditären Stoffwechselerkrankungen erfolgen. Alle sechs Monate ist eine Kontrolluntersuchung durch das o.a. Zentrum oder den/die o. a Facharzt/Fachärztin durchzuführen.<br> \\nCERDELGA darf nicht mit anderen für die Indikation Morbus Gaucher zugelassenen Medikamente kombiniert werden.<br> \\nDer behandelnde Arzt ist verpflichtet Patienten auf Cerdelga Behandlung laufend im International Collaborative Gaucher Group (ICGG) Registry (clinicaltrials.gov NCT00358943) (https://www.registrynxt.com/) zu erfassen. Sofern ein Patient keine Einwilligung zur Erfassung seiner Daten in das Register gibt, muss dies ausgewiesen werden.<br> \\n<br>\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2022-06-01\",\"validTo\":null}]",
  "galenic_form": "Kaps 84 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-06-01",
  "self_retention_pct": 10
}

See everything about eliglustat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.